Clinical Trial Update: Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating long-term efficacy of once-daily versus twice-daily aspirin in high-risk myeloproliferative neoplasm patients with aspi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: Siriraj Hospital | Conditions: Myeloproliferative Neoplasms (MPN) | Phase 3 | Status: RECRUITING